<DOC>
	<DOCNO>NCT02211209</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety volanesorsen give 52 week patient Familial Chylomicronemia Syndrome</brief_summary>
	<brief_title>The APPROACH Study : A Study Volanesorsen ( Formerly ISIS-APOCIIIRx ) Patients With Familial Chylomicronemia Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type I</mesh_term>
	<criteria>History chylomicronemia A diagnosis Familial Chylomicronemia Syndrome ( Type 1 Hyperlipoproteinemia ) Fasting triglyceride ≥ 750 mg/dL ( 8.4 mmol/L ) Screening Diabetes mellitus newly diagnose HbA1c ≥ 9.0 % Other type severe hypertriglyceridemia Active pancreatitis within 4 week screen Acute Coronary Syndrome within 6 month screen Major surgery within 3 month screen Treatment Glybera therapy within 2 year screen Previous treatment ISISAPOCIIIRx Have condition opinion investigator could interfere patient participate completing study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>